Background: TRAF6, a member of the tumour necrosis factor receptor-associated factor family, was first identified as a transducer of CD40 and interleukin-1 receptor (IL-1R) signals based on the interaction of TRAF6 with the cytoplasmic tail of CD40 and with the IL-1R associated kinase in vitro. However, the functions of TRAF6 in vivo remain unidentified.
CD40 signalings play crucial roles in B-cell function.To identify molecules which transduce CD40 signalings, we have utilized the yeast two-hybrid system to clone cDNAs encoding proteins that bind the cytoplasmic tail of CD40. A cDNA encoding a putative signal transducer, designated TRAF6, has been molecularly cloned. TRAF6 has a tumor necrosis factor receptor (TNFR)-associated factor (TRAF) domain in its carboxyl terminus and has a RING finger domain, a cluster of zinc fingers and a coiled-coil domain, which are also present in other TRAF family proteins. TRAF6 does not associate with the cytoplasmic tails of TNFR2, CD30, lymphotoxin- receptor, and LMP1 of Epstein-Barr virus. Deletion analysis showed that residues 246 -269 of CD40 which are required for its association with TRAF2, TRAF3, and TRAF5 are dispensable for its interaction with TRAF6, whereas residues 230 -245 were required. Overexpression of TRAF6 activates transcription factor NFB, and its TRAF-C domain suppresses NFB activation triggered by CD40 lacking residues 246 -277. These results suggest that TRAF6 could mediate the CD40 signal that is transduced by the amino-terminal domain (230 -245) of the CD40 cytoplasmic region and appears to be independent of other known TRAF family proteins.
Constitutive nuclear factor (NF)-kB activation is thought to be involved in survival, invasion, and metastasis in various types of cancers. However, neither the subtypes of breast cancer cells with constitutive NF-kB activation nor the molecular mechanisms leading to its constitutive activation have been clearly defined. Here, we quantitatively analyzed basal NF-kB activity in 35 human breast cancer cell lines and found that most of the cell lines with high constitutive NF-kB activation were categorized in the estrogen receptor negative, progesterone receptor negative, ERBB2 negative basal-like subtype, which is the most malignant form of breast cancer. B reast cancer is a disease of the mammary epithelium, which is composed of two major types of differentiated cells: luminal epithelial cells and basal or myoepithelial cells.(1) Recent studies have identified self-renewing pluripotent stem cells in mammary epithelium and suggest a model in which these stem cells could differentiate into the luminal-or basal-restricted lineages. Molecular taxonomic analyses of breast cancers by gene expression profiling have identified five breast cancer subtypes: luminal A, luminal B, basal-like, ERBB2-positive, and normal breast-like.(2) This classification is closely associated with the differentiation model of mammary epithelium. Luminal-and basallike breast cancer subtypes express genes characteristic of the two distinct types of epithelial cells. These subtypes show different clinical courses and responses to therapeutic agents. The basallike subtype has been associated with aggressive behavior and poor prognosis and typically does not express estrogen receptor (ER), progesterone receptor (PR), or ERBB2 ("triple-negative" phenotype).(3) Therefore, patients with basal-like subtype are unlikely to benefit from currently available targeted therapeutic strategies, such as hormone therapy and Herceptin (Roche, Basel, Switzerland). It is thus crucial to identify effective molecular targets for this subtype of breast cancer.Nuclear factor (NF)-κB transcription factors are important regulators of the genes necessary for innate and adaptive immune responses and for the survival and proliferation of certain cell types. The NF-κB family is composed of five different proteins, including RelA, RelB, c-Rel, and the precursor and processed products of the NFKB1 (p105/p50) and NFKB2 (p100/p52) genes.These proteins homodimerize and/or heterodimerize to form active transcription factors. Two distinct NF-κB pathways have been proposed: the classical pathway, which activates the RelA-p50 complex, and the alternative pathway, which activates the RelBp52 complex.(4) In normal cells, activation of the classical and alternative pathways is tightly regulated by inhibitor of NF-κB (IκB) family proteins and a p100 protein, respectively. Both NF-κB pathways are aberrantly activated and involved in tumor development in various cancers, including breast cancer.(5,6) Previous studies have revealed that hormone-independent breast cancer cells exhibit cons...
ErbB2-negative breast tumors represent a significant therapeutic hurdle because of a lack of effective molecular targets. Although NOTCH proteins are known to be involved in mammary tumorigenesis, the functional significance of these proteins in ErbB2-negative breast tumors is not clear. In the present study, we examined the expression of activated NOTCH receptors in human breast cancer cell lines, including ErbB2-negative and ErbB2-positive cell lines. Activated NOTCH1 and NOTCH3 proteins generated by ;-secretase were detected in most of the cell lines tested, and both proteins activated CSL-mediated transcription. Down-regulation of NOTCH1 by RNA interference had little or no suppressive effect on the proliferation of either ErbB2-positive or ErbB2-negative cell lines. In contrast, down-regulation of NOTCH3 significantly suppressed proliferation and promoted apoptosis of the ErbB2-negative tumor cell lines. Down-regulation of NOTCH3 did not have a significant effect on the ErbB2-positive tumor cell lines. Down-regulation of CSL also suppressed the proliferation of ErbB2-negative breast tumor cell lines, indicating that the NOTCH-CSL signaling axis is involved in cell proliferation. Finally, NOTCH3 gene amplification was detected in a breast tumor cell line and one breast cancer tissue specimen even though the frequency of NOTCH3 gene amplification was low (<1%). Taken together, these findings indicate that NOTCH3-mediated signaling rather than NOTCH1-mediated signaling plays an important role in the proliferation of ErbB2-negative breast tumor cells and that targeted suppression of this signaling pathway may be a promising strategy for the treatment of ErbB2-negative breast cancers.
Tumor necrosis factor receptor (TNFR)-associated factor 6 (TRAF6) is an adapter protein that links signals from members of the TNFR superfamily and Toll͞IL-1 receptor family to activation of transcription factors NF B and AP-1. Analysis of TRAF6-deficient mice revealed that TRAF6 is essential for normal bone formation and establishment of immune and inflammatory systems. Here we report that TRAF6 deficiency results in defective development of epidermal appendixes, including guard hair follicles, sweat glands, sebaceous glands of back skin, and modified sebaceous glands such as meibomian glands, anal glands, and preputial glands. Except the sebaceous gland impairment, these abnormal phenotypes are identical to those observed in Tabby (Ta), downless (dl), and crinkled (cr) mice, which are models of hypohidrotic (anhidrotic) ectodermal dysplasia in human. -catenin and mucosal addressin cell adhesion molecule-1, an early marker of developing guard-hair follicles is absent in the skin of TRAF6-deficient embryos. Thus, TRAF6 is essential for development of epidermal appendixes. TRAF6 does not associate with the cytoplasmic tail of the dl protein (DL)͞ectodysplasin receptor (EDAR) receptor, which, when mutated, results in hypohidrotic (anhidrotic) ectodermal dysplasia. However, TRAF6 associates with X-linked ectodysplasin-A2 receptor (XEDAR) and TNFR super family expressed on the mouse embryo (TROY͞toxicity and JNK inducer (TAJ), which are EDAR-related members of the TNFR superfamily that are expressed at high level in epidermal appendixes. Furthermore, TRAF6 is essential for the XEDAR-mediated NF B activation. Our results suggest that TRAF6 may transduce signals emanating from XEDAR or TROY͞TAJ that are associated with development of epidermal appendixes.
CD40 signaling modulates the immune response at least in part by activation of nuclear factor B (NFB). It has been shown that two distinct domains in the CD40 cytoplasmic tail (cyt), namely cyt-N and cyt-C, independently activate NFB. Although four members of the tumor necrosis factor receptor-associated factor (TRAF) family, including TRAF2, TRAF3, TRAF5, and TRAF6, bind to the CD40 cyt, how each TRAF protein contributes to the NFB activation by CD40 is not clear. Here we report that TRAF2, TRAF3, and TRAF5 bind cyt-C, whereas TRAF6 binds cyt-N. cyt-N is conserved poorly between human and mouse CD40, while cyt-C is highly conserved. However, single aa substitution of Glu-235 in cyt-N of human CD40 with Ala abolishes the binding of TRAF6 to cyt-N and NFB activation by cyt-N. Conservation of this Glu between mouse and human CD40 strongly suggests that TRAF6 could link cyt-N to signals essential for CD40-mediated immune response. Furthermore, NFB activation by cyt-C is inhibited by a kinase-negative form of NFB-inducing kinase more efficiently than that by cyt-N, consistent with the result that NFB activation by TRAF2 and TRAF5 is inhibited by a kinase-negative form of NFB-inducing kinase more efficiently than that by TRAF6. These results indicate that NFB activating signals emanating from cyt-N and cyt-C are mediated by the different members of the TRAF family and could be regulated in a distinct manner.CD40 is a member of the tumor necrosis factor receptor (TNFR) superfamily, which includes TNFR-1, TNFR-2, Fas, lymphotoxin- receptor, CD27, CD30, OX40, and the lowaffinity nerve growth factor receptor (1). CD40 is expressed in late B cells in bone marrow, mature B cells, and certain accessory cells, including bone marrow-derived dendritic cells and follicular dendritic cells (2, 3), and is a receptor for CD40 ligand (CD40L), which is present on activated CD4 ϩ T cells (4). Signaling through CD40 rescues B cells from apoptosis induced by crosslinking of the surface IgM complex (5), induces B cells to undergo Ig isotype switching (6, 7), and activates antigen-presenting cells to prime cytotoxic T lymphocytes (8-10).CD40 signaling events are reported to include modulation of the activity of nonreceptor-type tyrosine kinases such as Lyn, Fyn, and Syk, activation of phosphatidylinositol-3-kinase, phosphorylation of phospholipase C␥2 (11-13), and activation of the Rel͞nuclear factor B (NFB) transcription factors (14). CD40 signaling is also linked to the induction of the B7 (15), intercellular adhesion molecule-1 (16, 17), Fas (18), CD23 (19), lymphocyte function-associated antigen-1 (16), Bcl-X L , Cdk4 and Cdk6 proteins (20). However, the molecular mechanism of signal transduction from CD40 is not clear. The cytoplasmic tail (cyt) of TNFR superfamily members lacks sequences indicative of catalytic activity, but is associated with a family of signal transducer proteins, the TNFR-associated factor (TRAF) family. Among the six members of the TRAF family, TRAF2 (21), TRAF3 (also known as CD40bp, LAP-1, or CRAF1) ...
DRG1 and DRG2 comprise a highly conserved subfamily of GTP-binding proteins and are thought to act as critical regulators of cell growth. Their abnormal expressions may trigger cell transformation or cell cycle arrest. Our aim is to clarify their physiological functions and regulatory mechanisms. Here we report identification of novel proteins, D RG f amily r egulatory p rotein (DFRP) 1 and DFRP2, which regulate expression of DRG proteins through specific binding. In transient transfection experiments, DFRP1 specifically binds DRG1, and DFRP2 preferentially binds DRG2. DFRPs provide stability to the target DRG proteins through physical association, possibly by blocking the poly-ubiquitination that would precede proteolysis of DRG proteins. DFRPs are highly conserved in eucaryotes, and the expression patterns of dfrp1 and drg1 transcripts in Xenopus embryos and tissues are similar, indicating that these genes work cooperatively in various types of eukaryotic cells. Immunofluorescence experiments have revealed that the interaction between DRG1 and DFRP1 may occur in the cytoplasm. We generated dfrp1 -knockout cells and found that endogenous expression of DRG1 is regulated by DFRP1, confirming that DFRP1 is a specific up-regulator of DRG1 in vivo . On the basis of these results, we propose that DRG1 and DRG2 are regulated differently despite their structural similarities.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
334 Leonard St
Brooklyn, NY 11211
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.